Gilead Sciences
GILD
$134.28
-1.48%
Gilead Sciences is a biopharmaceutical company that develops and markets therapies for life-threatening infectious diseases, primarily HIV and hepatitis B and C, and is expanding into oncology through acquisitions. As a dominant player in the HIV market and a growing force in oncology via CAR-T therapies (Yescarta/Tecartus) and Trodelvy, Gilead distinguishes itself through a strong antiviral franchise and strategic bolt-on acquisitions. The current investor narrative centers on Gilead's aggressive acquisition strategy to bolster its oncology pipeline, including the $7.8 billion Arcellx deal and $3 billion Tubulis acquisition, while managing the impact of failed trial results and navigating a mixed near-term revenue outlook.…
GILD
Gilead Sciences
$134.28
Related headlines
GILD 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Gilead Sciences's 12-month outlook, with a consensus price target around $158.30 and implied upside of +17.9% versus the current price.
Average Target
$158.30
0 analysts
Implied Upside
+17.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$120 - $180
Analyst target range
Gilead is covered by 27 analysts, with a consensus recommendation of 'Buy' (mean recommendation 1.62 on a 1-5 scale, where 1 is Strong Buy). The average target price is $158.30, implying approximately 20.2% upside from the current price of $131.70. The distribution leans bullish, with recent ratings from Morgan Stanley (Overweight), Truist (Buy), and HSBC (upgraded from Hold to Buy) indicating positive sentiment. The target range spans from a low of $120.00 to a high of $180.00. The high target of $180 assumes successful pipeline execution, particularly in oncology (Arcellx, Tubulis), and potential multiple expansion. The low target of $120 reflects risks from failed trials, competitive pressure on HIV drugs, or acquisition integration challenges. The spread between low and high ($60) is 38% of the average target, indicating moderate uncertainty. Recent analyst actions show mostly reaffirmations or upgrades, with HSBC upgrading from Hold to Buy in July 2026, suggesting improving sentiment. The wide range and bullish consensus suggest that while the outlook is positive, there is significant debate about the pace and magnitude of growth from the pipeline.
Drowning in data?
Find the real signal!
Bulls vs Bears: GILD Investment Factors
Gilead presents a balanced risk/reward profile. The bull case is supported by strong profitability, attractive valuation (forward P/E 13.6x, 20% upside to analyst target), robust free cash flow, and a dominant HIV franchise. The bear case centers on modest revenue growth, failed pipeline trials (Trodelvy), and significant acquisition integration risk. Currently, the bull case has slightly stronger evidence given the valuation discount and cash flow strength, but the single most important tension is the success of the oncology pipeline—if the Arcellx and Tubulis programs deliver, the stock could re-rate higher; if they fail, the growth narrative collapses. The stock is best suited for value-oriented investors seeking income and downside protection.
Bullish
- Strong Profitability and Margin Expansion: Net margin improved from 19.7% in Q1 2025 to 29.0% in Q1 2026, while operating margin rose from 33.6% to 37.2%. Net income grew 53.7% YoY to $2.021 billion, demonstrating significant operating leverage.
- Attractive Valuation with 20% Upside: Forward P/E of 13.6x is near the low end of its 5-year range (10-26x) and at a 19% discount to the industry median of ~22x. The average analyst target of $158.30 implies 20.2% upside from $131.70.
- Robust Free Cash Flow Generation: TTM free cash flow is $10.229 billion, with $2.427 billion generated in Q1 2026 alone. This provides ample capacity for the aggressive acquisition strategy ($7.8B Arcellx, $3B Tubulis) and a well-covered dividend (payout ratio 47%).
- Dominant HIV Franchise Provides Stability: HIV segment contributed $5.03 billion in Q1 2026, representing 72% of total revenue. This core business provides predictable cash flows and a strong moat, with low beta (0.34) reducing downside risk.
Bearish
- Failed Trodelvy Trial Raises Pipeline Doubts: Gilead and Merck ended the Trodelvy-Keytruda lung cancer trial in June 2026, highlighting the high-risk nature of oncology drug development. This setback undermines confidence in the oncology pipeline, which is central to the growth thesis.
- Revenue Growth Remains Modest: Q1 2026 revenue of $6.96B grew only 4.4% YoY, and quarterly revenue has been flat around $7B for the past year. The 7.9% YoY growth in Q4 2025 was not sustained, indicating a deceleration.
- Acquisition Integration and Execution Risk: The $7.8B Arcellx and $3B Tubulis deals, along with the $1.5B Ouro Medicines acquisition, total over $12B in recent M&A. Integrating these acquisitions and delivering on pipeline promises carries significant execution risk.
- High Debt-to-Equity Ratio: Debt-to-equity of 1.08x is elevated, reflecting the debt-funded acquisition strategy. While free cash flow covers interest, a downturn or failed pipeline could strain the balance sheet.
GILD Technical Analysis
Gilead is in a broad uptrend over the past year, with a 1-year price change of +20.76%, but the stock has pulled back from its 52-week high of $157.29. Currently trading at $131.70, the stock sits at 83.7% of its 52-week range, suggesting it is in the upper half but off the peak, indicating a consolidation phase after a strong run. The 1-year relative strength vs. SPY is slightly negative at -0.16%, implying the stock has underperformed the market slightly over the long term. Short-term momentum shows a divergence: the 1-month change is +5.95%, while the 3-month change is -4.94%, indicating a recent recovery from a deeper pullback. The 1-month relative strength vs. SPY is +5.35%, showing near-term outperformance, but the 3-month relative strength is -11.23%, confirming the intermediate-term weakness. This divergence suggests the stock may be attempting to reverse its 3-month downtrend, but the recovery is still nascent. Key support is at the 52-week low of $107.75, while resistance is at the 52-week high of $157.29. A breakout above $157.29 would signal a resumption of the uptrend, while a breakdown below $107.75 would indicate a bearish reversal. With a beta of 0.34, Gilead is significantly less volatile than the market, making it a lower-risk holding that may lag during market rallies but provide downside protection.
Beta
0.34
0.34x market volatility
Max Drawdown
-22.0%
Largest decline past year
52-Week Range
$108-$157
Price range past year
Annual Return
+23.4%
Cumulative gain past year
| Period | GILD Return | S&P 500 |
|---|---|---|
| 1m | +7.0% | +0.3% |
| 3m | -2.4% | +4.7% |
| 6m | +7.5% | +7.5% |
| 1y | +23.4% | +18.4% |
| ytd | +10.4% | +9.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
GILD Fundamental Analysis
Gilead's revenue trajectory shows modest growth, with Q1 2026 revenue of $6.96 billion, up 4.4% year-over-year from $6.667 billion in Q1 2025. However, revenue has been relatively flat over the past four quarters, ranging from $6.96B to $7.924B, indicating a deceleration from the 7.9% YoY growth seen in Q4 2025. The HIV segment remains the core driver, contributing $5.03 billion in Q1 2026, while oncology products (Trodelvy at $402M and cell therapy at $482M) are growing but still a small portion of total revenue. The growth trajectory is stable but unexciting, with the investment case hinging on pipeline success rather than top-line acceleration. Profitability is robust, with a net income of $2.021 billion in Q1 2026 and a net margin of 29.0%, up from 19.7% in Q1 2025. Gross margin is high at 79.2%, and operating margin improved to 37.2% from 33.6% a year ago, reflecting operating leverage. The company is consistently profitable, with net income growing from $1.315B in Q1 2025 to $2.021B in Q1 2026, a 53.7% increase, driven by higher revenue and margin expansion. Gilead has a strong balance sheet with a debt-to-equity ratio of 1.08 and a current ratio of 1.68, indicating adequate liquidity. Free cash flow (TTM) is $10.229 billion, providing ample capacity for acquisitions and dividends. The company generated $2.427 billion in free cash flow in Q1 2026 alone, and with a payout ratio of 47%, dividends are well-covered. ROE is 37.5%, reflecting high profitability relative to equity, though leverage contributes to this figure.
Quarterly Revenue
$7.0B
2026-03
Revenue YoY Growth
+4.4%
YoY Comparison
Gross Margin
79.2%
Latest Quarter
Free Cash Flow
$10.2B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is GILD Overvalued?
Since Gilead has positive net income, the primary valuation metric is the P/E ratio. The trailing P/E is 17.9x, while the forward P/E is 13.6x, implying the market expects earnings growth. The gap between trailing and forward P/E suggests analysts anticipate a 32% increase in earnings over the next year, consistent with the estimated EPS growth. Compared to the industry average (Drug Manufacturers - General), Gilead's trailing P/E of 17.9x is at a discount to the sector median of approximately 22x, representing a 19% discount. This discount may be justified by Gilead's slower revenue growth relative to some peers, but its high margins and strong cash flow support a fair valuation. Historically, Gilead's trailing P/E has ranged from about 10x to 26x over the past five years. The current 17.9x is near the middle of this range, suggesting the stock is fairly valued relative to its own history. The P/E was as low as 10.7x in Q3 2023 and as high as 26.4x in Q1 2025, so the current level does not indicate extreme overvaluation or undervaluation. The forward P/E of 13.6x is near the lower end of the historical range, which could imply upside if earnings materialize as expected.
PE
17.9x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 8x~26x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
12.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Gilead's debt-to-equity ratio of 1.08x is elevated, reflecting its aggressive acquisition strategy. While TTM free cash flow of $10.2 billion covers interest expenses comfortably, a failed pipeline or revenue decline could strain the balance sheet. Revenue growth is modest at 4.4% YoY, and the reliance on the HIV segment (72% of revenue) creates concentration risk. The net margin improvement to 29% is positive, but it may not be sustainable if R&D spending increases for pipeline development.
Market & Competitive Risks: The stock's beta of 0.34 indicates low market correlation, but it has underperformed the S&P 500 by 11.23% over 3 months. Valuation compression risk exists if the forward P/E of 13.6x expands, but it is already near historical lows. Competitive threats include new HIV therapies from other firms and the failure of Trodelvy in lung cancer, which undermines oncology credibility. Regulatory risks include drug pricing pressures and tariffs (100% drug tariffs proposed), though Gilead may have exemptions.
Worst-Case Scenario: A chain of events including further pipeline failures (e.g., Arcellx or Tubulis disappointing), revenue deceleration below 4%, and a broader market sell-off could drive the stock to its 52-week low of $107.75. This represents a potential 18.2% downside from the current price of $131.70. In a severe scenario, if the dividend is cut and earnings disappoint, the stock could test the $100 level, implying a 24% loss.
